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We examined the antitumour effect of a combination of betulinic acid (BA) and vincristine (VCR) on murine melanoma B16F10 cells
in vitro and in vivo. Betulinic acid, a pentacyclic triterpene, showed a synergistic cytotoxic effect on melanoma cells by combinational
use of VCR. Betulinic acid and VCR induced cell cycle arrest at different points (BA at G1 phase and VCR at G2/M phase) and caused
apoptosis in B16F10 melanoma cells. In the in vivo study, VCR inhibited metastasis of tumour cells to the lung. The addition of BA to
VCR augmented suppression of the experimental lung metastasis of melanoma cells in C57BL/6 mice. The number of lung nodules of
more than 1mm in diameter in mice treated with BA and VCR was less than that in mice treated with VCR alone. These results
suggest that BA is an effective supplement for enhancing the chemotherapeutic effect on malignant melanoma.
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When multiple metastases are found at the time of clinical
diagnosis, surgical operations are usually not performed, and the
patients are treated mainly by radiotherapy or chemotherapy with
various anticancer drugs. To investigate the effects of anticancer
drugs on tumour cells and their lung metastasis, the experimental
lung metastasis model by Fidler and Kripke (1977) has been used
(Miyoshi et al, 2000). Although anticancer drugs are widely used
for cancer therapy, a sufficient quantity of the drug for treatment
cannot be administered in many cases due to severe side effects.
Malignant melanoma is difficult to cure. Since melanoma cells
have the ability to spread to distal organs, various anticancer drugs
have been used in combination to try to improve the therapeutic
effect on malignant melanoma. For example, lovastatin has been
shown to potentiate the antitumour activity of doxorubicin in
murine melanoma (Feleszko et al, 2002), and exisulind in
combination with docetaxel has been shown to inhibit the growth
and metastasis of human lung cancer (Chan et al, 2002). Recently,
the antitumour effect of combinational therapy using an anticancer
drug and a phytochemical has been studied (Darzynkiewicz, 1995;
Christensen and LeBlanc, 1996; Singh et al, 2002). Phytochemicals
such as flavonoid have relatively low levels of toxicity (Singh et al,
2002) and can induce apoptosis or cell cycle arrest in tumour-
derived cells (Darzynkiewicz, 1995). We previously reported that
an extract of a medicinal plant lemon grass containing various
phytochemicals inhibited the formation of azoxymethane-induced
DNA adducts and aberrant crypt foci in the rat colon (Suaeyun
et al, 1997).
Betulinic acid (BA), a pentacyclic triterpene isolated from the
root bark of Morus australis or Clerodendrum mandarinorum and
many other medicinal plants (Zhu et al, 1996; Ko et al, 1997), has
recently been reported to have cytotoxic activity against several
tumour cell lines (Pisha et al, 1995; Fulda et al, 1997, 1998; Wick
et al, 1999; Kwon et al, 2002; Wachsberger et al, 2002). Betulinic
acid is a novel experimental antineoplastic agent for human
melanoma cells in vitro (Pisha et al, 1995; Wachsberger et al,
2002). Betulinic acid also induces apoptosis in neuroectodermal
tumour and glioma cells (Fulda et al, 1997, 1998; Wick et al, 1999).
Furthermore, BA has been shown to inhibit growth factor-induced
angiogenesis in vitro (Kwon et al, 2002).
Vincristine (VCR) is one of the major chemotherapeutic agents
used for the treatment for malignant melanoma. Vincristine
showed antitumour effects on B16 melanoma cells, but a high dose
of VCR induces severe bone marrow toxicity (Morrow et al, 1987).
In this study, we evaluated the effectiveness of combination
therapy with VCR and BA for malignant melanoma by examining
the synergistic cytotoxic activity against B16F10 melanoma cells in
vitro and in vivo.
MATERIALS AND METHODS
Chemicals
Betulinic acid, VCR, annexin V–FITC and propidium iodide (PI)
solution was obtained from Wako Pure Chemical Industries, Ltd,
Osaka, Japan. Triton X-100, proteinase K, agarose and boric acid
were obtained from Sigma Chemical Co., St Louis, MO, USA.
Betulinic acid and VCR were dissolved in dimethyl sulphoxide
(DMSO) and saline, respectively. They were diluted with saline
to appropriate concentrations and stored in a refrigerator at 41C
until use.
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sAnimal model
Female C57BL/6 mice (9–10 weeks old) obtained from SLC Japan
(Hamamatsu, Japan) were housed in plastic cages with sawdust
bedding and given food and water ad libitum. The room in which
the mice were kept, in the Institute of Animal Experimentation,
School of Medicine, The University of Tokushima, Japan, was
environmentally controlled at a temperature of 23721C and
humidity of 55710% and with a 13-h light/11-h dark cycle. All
animal experiments were carried out with approval by the
Institutional Animal Care and Use Committee of the University
of Tokushima School of Medicine, and met the standards required
by the United Kingdom Coordinating Committee on Cancer
Research (UKCCCR) guidelines (Workman et al, 1998).
Cell culture conditions
B16F10 melanoma cells were purchased from the American Type
Culture Collection (Virginia, USA) and were maintained in DMEM
medium (Nissui Pharmaceutical Co., Japan) supplemented with
5% calf serum (Gibco Co., NY, USA), 5% horse serum (Gibco),
penicillin–streptomycin mix (Gibco) and gentamycin (Gibco).
B16F10 melanoma cells were passaged every 3–4 days.
Annexin V-based apoptosis analysis
B16F10 melanoma cells (1 10
5) were cultured in 25cm
2 tissue
culture plates for 24h before the treatment with test reagents.
Betulinic acid at concentrations of 1, 2.5 and 5mM or VCR at a
concentration of 1nM was added, and the cells were incubated for a
further 24h. After the incubation, the cells were trypsinised,
washed with phosphate-buffered saline (PBS), and suspended in
1ml of a calcium-containing binding buffer. Then 5ml of annexin
V–FITC and 5ml of PI were added to the cell suspensions. After
10-min incubation at room temperature, early apoptotic cells
(annexin V positive and PI negative) and late apoptotic/necrotic
cells (annexin V positive and PI positive) as well as living cells
(annexin V negative and PI negative) were detected by a flow
cytometer (Coulter Epics XL-MCL, Beckman Coulter, Tokyo,
Japan). The data were analysed using CellQuest software. The
early and late apoptotic cells (annexin V positive) were defined as
the apoptotic population.
DNA fragmentation-based apoptosis analysis
Total DNA was extracted according to the method of Lee and
Shacter (1999). Briefly, B16F10 melanoma cells (2 10
6) were
cultured in 60cm
2 tissue culture plates for 24h before the
treatment with test reagents. Betulinic acid at concentrations of
1, 2.5 and 5mM was added, and the cells were incubated for a
further 24h. Cells were harvested, washed with PBS and lysed in
buffer containing 10mM Tris-HCl (pH 7.8), 10mM EDTA, 0.5%
Triton X-100, 200mgml
 1 RNaseA and 200mgml
 1 proteinase K.
After DNA was precipitated with isopropanol, it was then
resuspended in a Tris-EDTA solution. Samples were resolved by
electrophoresis on 2% agarose gels and visualised by ethidium
bromide staining and UV transillumination.
Cell cycle distribution analysis
The effect of BA or VCR on cell cycle distribution in vitro was
determined by using a flow cytometer. B16F10 melanoma cells
(1 10
6) were cultured in 25cm
2 tissue culture plates for 24h
before the treatment with test reagents. After 24 or 36h of
incubation with BA at concentrations of 1, 2.5 and 5mM or VCR at
a concentration of 1nM, B16F10 melanoma cells were fixed with
99% ethanol, treated with RNaseA and stained with PI solution
containing RNase A. A flow cytometer was used to determine the
percentages of cells in G0/G1, S and G2/M phases of the cell cycle.
MTS assay
The standard MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, innersalt so-
lution) (Takara Co., Kusatsu, Japan) assay was performed to
examine cytostatic/cytotoxic effects of BA and/or VCR on B16F10
melanoma cells according to the manufacturer’s instructions.
Briefly, tumour cells (5 10
3 cells) were seeded in 96-well
microtiter plates (Becton Dickinson Co., Franklin Lakes, NJ,
USA). After an overnight incubation at 371Ci n5 %C O 2, serially
diluted solutions of BA, VCR or both were added in triplicate to a
final volume of 200ml. After incubation for 24h, the medium was
removed, and the cells were washed twice with culture medium
and resuspended in 200ml of culture medium. Then, 20ml of MTS
was added to each well, and the plates were incubated at 371C for
1h. The absorbance of each well was read at 450nm on a
microplate reader (microplate reader: MTP-120, Corona Co.,
Katsuta, Japan). The relative viability was calculated as follows:
relative viability¼[(experimental absorbance background absor-
bance)C(absorbance of untreated controls background
absorbance)] 100%.
Drug interaction analysis
Synergistic interaction between BA and VCR was determined by
using isobologram analysis as described in detail previously
(Berenbaum, 1981; Sora et al, 1994). Briefly, inhibition of cell
proliferation was determined as described above. Equieffective
concentrations were used for the analysis. The interaction index
for the two-drug combination was computed by the following
equation: interaction index¼BAc/BAeþVCRc/VCRe, where BAe
and VCRe are concentrations of BA and VCR, respectively, that
inhibit cell proliferation to 40% of the control level when used
alone, and BAc and VCRc are concentrations of BA and VCR,
respectively, that produce the same effect when used in combina-
tion. According to this method, an interaction index of less than
1.0 indicates synergistic interaction between two drugs. An
interaction index of more than 1.0 indicates antagonism, and an
index of 1.0 indicates additive interaction.
Effects of BA and VCR and their combination on tumour
development in C57BL/6 mice injected with B16F10
melanoma cells
On day 0, B16F10 melanoma cells (1 10
5 cells/0.1ml medium)
were injected into the tail veins of anaesthetised 9- to 10-week-old
female C57BL/6 mice. Tumour-bearing mice were divided into four
groups (five mice in each group) and treated intraperitoneally
(i.p.) with saline (0.1ml), BA (10mgkg
 1day
 1), VCR
(0.065mgkg
 1day
 1) or a combination of both drugs (BA,
10mgkg
 1day
 1; VCR, 0.065mgkg
 1day
 1) (Figure 1). The dose
of BA for the treatment of mice was decided by referring to a
previous report (Pisha et al, 1995). Body weights of mice were
recorded every 4 days to determine whether the treatment
influenced health status. The mice were killed by cervical
dislocation under anaesthesia with diethyl ether 17 days after
inoculation of tumour cells. The lungs were removed, and two
independent observers determined the numbers and sizes of lung
metastatic nodules.
Data analysis
All data were statistically analysed by analysis of variance. Po0.05
was considered to be statistically significant.
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sRESULTS
Effects of VCR and/or BA on the growth of B16F10
melanoma cells in vitro
Vincristine is one of the major chemotherapeutic agents for
patients with malignant melanoma. To determine whether treat-
ment with a combination of VCR and BA has a greater inhibitory
effect than does treatment with VCR or BA alone, we examined the
inhibitory effects of VCR alone, BA alone and the combination of
them using MTS assays. When the growth level of untreated cells
was regarded as 100%, the growth levels of cells treated with 0.1, 1
and 10nM VCR were 83.4, 71.2 and 56.2%, respectively (Figure 2).
Vincristine inhibited the growth of B16F10 cells in a dose-
dependent manner. In addition, BA also inhibited the growth of
B16F10 cells in a dose-dependent manner (1mM, 92.5%; 2.5mM,
91.9%; 5mM, 62.0%). Combinational treatment with 1 or 10nM
VCR and BA resulted in the inhibition of the growth of B16F10
cells in a dose-dependent manner. The combination of 10nM VCR
and 5mM BA greatly inhibited the growth of cells (12.9%).
Induction of apoptosis in B16F10 cells by VCR and BA
B16F10 melanoma cells were incubated in DMEM medium with
VCR at 1nM or BA at three different concentrations (1, 2.5 and
5mM) for 24h. The percentage of apoptotic cells was determined as
described in Materials and methods. The apoptotic population of
untreated cells was 6.1%, while that of cells treated with 1nM VCR
was 25.2% (Figure 3). The apoptotic populations of cells treated
with 1, 2.5 and 5mM BA alone were 8.9, 15.2 and 19.5%,
respectively. Moreover, the induction of apoptosis was evaluated
by DNA fragmentation (Wyllie, 1980). DNA ladder formation was
detected (Figure 4), and the fragments were stained in a dose-
dependent manner. These findings indicate that BA induced
apoptosis in a dose-dependent manner.
Determination of the synergistic effect of VCR and BA
using isobologram analysis
To clarify the synergistic effect of VCR and BA on inhibition of the
growth of B16F10 cells, we used isobologram analysis by the
method of Berenbaum (1981). Treatment with VCR or BA resulted
in inhibition of the growth of B16F10 cells in a dose-dependent
manner (Figure 5a and b). The inhibitory concentration (IC40)o f
VCR alone and that of BA alone showing 40% of the control
growth level were 100nM and 10mM, respectively (Figure 5a and b).
When IC40 was determined by combinational use of both drugs, a
combination of 10nM VCR and 1.8mM BA, and a combination of
1n M VCR and 3mM BA showed 40% growth of the control
(Figure 5c). The interaction indices calculated by the equation
shown in Materials and methods were 0.28 and 0.31, which are less
than 1.0 (Figure 5d). The results of isobologram analysis showed
that treatment with a combination of VCR and BA synergistically
inhibited the growth of B16F10 cells.
Induction of G2/M arrest and G1 arrest by VCR and BA,
respectively
Cell cycle distribution analysis was performed to clarify the
mechanism of synergic inhibitory action on B16F10 melanoma
cells. B16F10 cells were incubated with VCR and BA for 24 or 36h
in the same manner as in the cell apoptosis assay. The proportions
of cells in the G2/M phase that had been treated with 1nM VCR for
24 and 36h were 29.3 and 79.8%, respectively (untreated group:
14.5% after 24h and 10.0% after 36h) (Table 1), indicating that
VCR induces cell cycle arrest at the G2/M phase. The population of
G0/G1 cells treated with BA for 24h increased in a dose-dependent
manner (1mM, 78.8%; 2.5mM, 86.1%; 5mM, 95.5%). Moreover, the
cell population in the G0/G1 phase after 36h of treatment was
constant (93%) regardless of the concentration (untreated group:
80%), indicating that BA induces cell cycle arrest at the G1 phase.
These results demonstrated that VCR and BA induce cell cycle
arrest at different stages.
Antimetastatic effects of VCR, BA and their combination
in C57BL/6 mice treated with B16F10 melanoma cells
To determine whether the augmenting effect of BA on the
cytotoxicity of VCR against B16F10 melanoma cells can be
reproduced in vivo, animal experiments were performed according
to the schedule shown in Figure 1. B16F10 cells formed 50.2720.7
nodules in the lung in the nontreatment group, whereas they
formed 28.075.4, 35.6718.8 and 12.479.5 nodules in the VCR,
BA and combinational administration groups, respectively
(Figure 6). Treatment with VCR (0.065mgkg
 1day
 1) alone or
in combination with BA (10mgkg
 1day
 1) significantly sup-
pressed the experimental metastasis. B16F10 melanoma cells
formed 36.0712.2 large nodules of more than 1mm in diameter
Days 8 3 17 14 7 1 10 0
Killed B16F10 cell inoculation
Group 2
Group 3 Saline Saline
Group 4
Group 1
VCR
VCR VCR
VCR
Saline
Saline Saline
BA BA
BA BA
Figure 1 Experimental protocol for animal experiment. Arrows indicate
the series of injection of saline, BA (BA, i.p., 10mgkg
 1) or VCR (VCR, i.p.,
0.065mgkg
 1). Mice in groups 1, 2 and 3 were administered saline, VCR
and BA, respectively. Mice in group 4 were administered both VCR and BA.
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Figure 2 Effects of VCR and/or BA on the growth of B16F10 cells.
Concentrations of VCR were 0nM (open box), 0.1nM (hatched box),
1.0nM (latticed box) and 10nM (closed box). Cytostatic/cytotoxic effects
were tested by MTS assays and expressed as the percentage of the control
growth (% of untreated control). Bars, mean7s.d.
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sin the lung in the nontreatment group, whereas they formed
14.072.0, 16.879.0 and 3.675.5 large nodules in the VCR, BA and
combinational administration groups, respectively. The ratios of
the number of large nodules to total metastatic nodules in the lung
in the nontreatment group and the VCR, BA and combinational
administration groups were 71.7, 50.0, 47.2 and 29.0%, respec-
tively, indicating that combinational treatment with VCR and BA
significantly suppresses the growth of B16F10 melanoma cells after
their colonisation in the lung. No weight loss was observed in any
mice treated with VCR, BA or both reagents (data not shown).
DISCUSSION
In most cases of malignant melanoma, distant metastasis is found
at the time of clinical diagnosis. It has been reported that the
median survival time of stage IV melanoma patients is about 6–7.5
months, the 5-year survival rate being approximately 6% (Bajetta
et al, 2002). Lung metastasis of melanoma cells from primary
lesions is an especially important factor influencing the prognosis
of patients. Therefore, the main treatment for malignant melanoma
is various chemotherapeutic agents. Various anticancer drugs,
including bleomycin, VCR, lomustine and dacarbazine, have been
used in recent years for treating patients with melanoma (Wo ¨ll
et al, 1999; Kivela et al, 2003). However, severe side effects of the
chemotherapeutic agents have limited the application of high-dose
chemotherapy or combination therapy with different anticancer
drugs for many cases of malignant melanoma (Bajetta et al, 2002).
Combinational treatment with different drugs that induce
different cell cycle arrest results in apoptosis in tumour cells
(Darzynkiewicz, 1986; Bhuyan and Groppi, 1989; Ko et al, 1997). It
was thought that treatment with the combination of BA and VCR
had a synergistic cytotoxic effect on tumour cells because
treatment with BA alone and treatment with VCR alone induced
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Figure 3 Apoptosis assay of B16F10 cells treated with VCR or BA. Flow cytometric analysis of apoptosis in B16F10 cells was performed by treatment
with VCR (1nM) and BA (1, 2.5 or 5mM) for 24h and by staining with annexin V–FITC and PI.
(M)
0 1 2.5 5
Betulinic acid Vincristine
1
(nM)
Figure 4 DNA fragmentation analysis of apoptosis in B16F10 cells
treated with BA.
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scell cycle arrest in different phases. Although BA did not induce
cell cycle arrest in glioma cells (Wick et al, 1999), we found that BA
induced the accumulation of B16F10 melanoma cells in the G1
phase after 24h of coincubation in a dose-dependent manner.
Moreover, BA induced the accumulation of 93% of B16F10 cells in
the G1 phase after 36h of coincubation. It is expected that
elucidation of the mechanism by which BA inhibits the growth of
B16F10 melanoma cells will lead to the establishment of effective
combinational regimens with other antitumour drugs with
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Figure 5 Effects of VCR and/or BA on the growth of B16F10 cells. Cytostatic/cytotoxic effects were tested by MTS assays and expressed as the
percentage of the control growth (A–C). Solid and dotted lines show 1 and 10nM VCR, respectively (C). The isobologram depicts the interaction between
BA and VCR in inhibiting the growth of B16F10 cells (D). The solid line shows concentrations of both drugs required to inhibit cell growth to 40% (IC40).
The dotted line shows concentrations of drugs required to produce the same degree of growth inhibition as that in the case of interactions being additive.
The numbers in boxes are interaction indices.
Table 1 Cell cycle distribution of B16F10 cells treated with VCR or BA
Cell cycle distribution (%)
G0/G1
a S
a G2/M
a
Treatment 24h
b 36h
b 24h
b 36h
b 24h
b 36h
b
None 74.1 80.7 11.4 9.3 14.5 10.0
VCR (1nM) 62.7 20.2 8.0 0.0 29.3 79.8
BA (1mM) 78.8 93.3 2.0 5.6 19.2 1.1
BA (2.5mM) 86.1 93.1 3.0 2.1 10.9 4.8
BA (5mM) 95.5 93.4 0.0 2.2 4.4 4.4
VCR¼vincristine; BA¼betulinic acid.
aCell cycle phase.
bIncubation time.
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Figure 6 Effects of VCR and/or BA on experimental metastasis in mice.
Mice were treated with a solvent (open box), 0.065mgkg
 1 VCR (hatched
box), 10mgkg
 1 BA (latticed box), and both drugs (closed box) as
described in Materials and methods. The numbers of tumour nodules were
evaluated with classification by size (all sizes and more than 1mm in
diameter). *
,**Significantly different from the control group (Po0.05 and
Po0.0001). ***Significantly different from the VCR group and the BA
group (Po0.05).
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sdifferent cytotoxic mechanisms for the treatment of malignant
melanoma. It has been reported that BA enhanced the levels of
BAX and BCL-2 proteins in glioma cells and induced apoptosis in
those cells (Wick et al, 1999). BA induces apoptosis via the
activation of caspases in neuroectodermal cells (Fulda et al, 1997).
However, the mechanism by which apoptosis is induced in B16F10
cells by BA remains to be determined. Cell arrest, damage to DNA
or stress to the cytoplasm or cell membrane may be the cause of
apoptosis (Aller et al, 1992; Gohen et al, 1992; Ko et al, 1997). We
believe that results of analysis of cell cycle distributions or
apoptotic pathways to determine mechanisms of cytotoxicity of
other chemotherapeutic agents used in the treatment for malignant
melanoma will open the gate for the establishment of effective
combinational therapeutic regimens against the still untreatable
malignant disease using BA.
We performed animal experiments to determine whether BA
and VCR show a suppressive effect on the growth or metastatic
state of B16F10 melanoma cells in vivo. Antimetastatic activity was
investigated by counting lung metastatic nodules as reported
previously (Jani et al, 1993; Kang et al, 2000; Feleszko et al, 2002),
because B16F10 melanoma cells preferentially induce lung
metastasis (Jani et al, 1993; Gude et al, 2001; Malafa et al, 2002).
Although treatment with VCR alone resulted in a significant
suppression of metastasis of melanoma cells to the lung, the
additional use of BA resulted in greater suppression than that in
the case of treatment with VCR alone. Treatment with a
combination of VCR and BA resulted in a significant reduction
in the numbers of lung nodules of more than 1mm in diameter in
mice compared with that in the case of treatment with VCR or BA
alone. These results suggest that BA potentiates the antitumour
activity of VCR also in vivo. For the establishment of metastasis,
tumour cells must leave the original tumour mass, invade the
surrounding tissue and then enter blood vessels. The next steps are
tumour cell attachment to endothelial cells in the blood vessel,
invasion and growth in the target organ (Liotta, 1986; Nicolson,
1988). We could not determine which metastatic steps were mainly
inhibited by the combinational treatment with BA and VCR;
however, the significant reduction in the number of lung
nodules of more than 1mm in diameter in the combinational
treatment group indicates their inhibitory effect on tumour growth
after attachment to target metastatic sites. Furthermore, we
observed no significant difference between weight losses in the
groups treated with VCR, BA and both, indicating that the
combination of BA and VCR might be an effective regime with side
effects of relatively small magnitude for the treatment of malignant
melanoma.
In summary, treatment with a combination of VCR and BA
resulted in synergistic suppression of cell growth in vitro and in
the prevention of B16F10 melanoma experimental metastasis by
direct suppression of cell growth in vivo. It is expected that BA can
augment antitumour activities of various drugs showing different
types of cytotoxic mechanisms.
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